|drug1247||Expiratory training device Wiki||1.00|
|drug899||Convalescent plasma Wiki||0.21|
|D012120||Respiration Disorders NIH||0.22|
|D012140||Respiratory Tract Diseases NIH||0.20|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
A randomized controlled clinical trial will be carried out using inspiratory and expiratory training devices on healthy subjects recruited in social networks and university environments. The aim will be to determine the effectiveness and safety in the prevention and severity of COVID-19 disease by a respiratory training with inspiratory and expiratory devices.
Description: Dichotomous categorical variable measured by "yes" or "no" responsesMeasure: COVID-19 disease diagnosis Time: Change from Baseline COVID-19 disease diagnosis at 8 weeks
Description: Dichotomous categorical variable measured by "slight" or "severe" responsesMeasure: COVID-19 disease symptoms severity Time: Change from Baseline COVID-19 disease symptoms severity at 8 weeks
Description: Polytomous categorical variable measured by adverse effects responsesMeasure: Adverse effects Time: Change from Baseline adverse effects at 8 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports